Immune correlates of vaccine protection against HIV-1 acquisition
L Corey, PB Gilbert, GD Tomaras, BF Haynes… - Science translational …, 2015 - science.org
The partial efficacy reported in the RV144 HIV vaccine trial in 2009 has driven the HIV
vaccine field to define correlates of risk associated with HIV-1 acquisition and connect these …
vaccine field to define correlates of risk associated with HIV-1 acquisition and connect these …
[HTML][HTML] Infectious RNA: human immunodeficiency virus (HIV) biology, therapeutic intervention, and the quest for a vaccine
Y van Heuvel, S Schatz, JF Rosengarten, J Stitz - Toxins, 2022 - mdpi.com
Different mechanisms mediate the toxicity of RNA. Genomic retroviral mRNA hijacks infected
host cell factors to enable virus replication. The viral genomic RNA of the human …
host cell factors to enable virus replication. The viral genomic RNA of the human …
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
HIV-1–specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc
receptors. Antibodies of the same epitope specificity but of a different subclass therefore can …
receptors. Antibodies of the same epitope specificity but of a different subclass therefore can …
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines
AW Chung, M Ghebremichael, H Robinson… - Science translational …, 2014 - science.org
The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in
Thailand, resulted in an estimated 31.2% efficacy against HIV infection. By contrast …
Thailand, resulted in an estimated 31.2% efficacy against HIV infection. By contrast …
[HTML][HTML] Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice
A subset of individuals infected with HIV-1 develops broadly neutralizing antibodies (bNAbs)
that can prevent infection, but it has not yet been possible to elicit these antibodies by …
that can prevent infection, but it has not yet been possible to elicit these antibodies by …
[HTML][HTML] Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
HX Liao, M Bonsignori, SM Alam, JS McLellan… - Immunity, 2013 - cell.com
The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with …
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with …
[HTML][HTML] Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable
regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate …
regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate …
[HTML][HTML] Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial
Neutralizing and non-neutralizing antibodies to linear epitopes on HIV-1 envelope
glycoproteins have potential to mediate antiviral effector functions that could be beneficial to …
glycoproteins have potential to mediate antiviral effector functions that could be beneficial to …
Vaccines and broadly neutralizing antibodies for HIV-1 prevention
Development of improved approaches for HIV-1 prevention will likely be required for a
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early …
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early …
Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection
JH Kim, JL Excler, NL Michael - Annual review of medicine, 2015 - annualreviews.org
RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1
acquisition. The prespecified analysis of immune correlates of risk showed that antibodies …
acquisition. The prespecified analysis of immune correlates of risk showed that antibodies …